The Role of Optic Nerve Sheath Fenestration in Leukemic Patients Having Increased Intracranial Pressure

Alexandria University

Status and phase

Unknown

Phase 3

Phase 2

Conditions

Leukemic Patients With Increased Intracranial Pressure

Optic Nerve Sheath Fenestration

Treatments

Procedure: optic nerve sheath fenestration

Study type

Interventional

Funder types

Other

Identifiers

NCT04431882

0304628

Details and patient eligibility

About

Optic nerve sheath fenestration (ONSF) first described by De Wecker in 1872 for the treatment of neuroretinitis. Since then, optic nerve sheath fenestration has become well established procedure for treatment of papilledema in medically uncontrolled patients of idiopathic intracranial hypertension.

Full description

Optic nerve sheath fenestration (ONSF) first described by De Wecker in 1872 for the treatment of neuroretinitis. Since then optic nerve sheath fenestration has become well established procedure for treatment of papilledema in medically uncontrolled patients of idiopathic intracranial hypertension. Indications for ONSF in cancer patients are not well established, but a few case reports have shown success of ONSF in patients with perineural metastasis of breast cancer, increased intracranial pressure with papilledema due to a brain tumor, leukemia and optic nerve sheath meningioma. This study is conducted to establish the role of optic nerve sheath Fenestration in leukemic patients mainly those suffering from acute lymphoblastic leukemia.

Enrollment

20 patients

Sex

All

Ages

6 to 18 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Evidence of progressive visual loss and papilledema did not improve despite the maximal medical therapy prescribed.
Informed written consent was obtained from the parents/care providers of the study participants.

Exclusion criteria